Selective p300 degradation via peptide PROTAC: a new therapeutic strategy for advanced prostate cancers

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{98cd40727b664fd895c394c0cb2af9c0,

title = "Selective p300 degradation via peptide PROTAC: a new therapeutic strategy for advanced prostate cancers",

author = "Wang, {Ling Yu}",

year = "2024",

month = aug,

doi = "10.1016/j.ebiom.2024.105245",

language = "英语",

volume = "106",

pages = "105245",

journal = "EBioMedicine",

issn = "2352-3964",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Selective p300 degradation via peptide PROTAC

T2 - a new therapeutic strategy for advanced prostate cancers

AU - Wang, Ling Yu

PY - 2024/8

Y1 - 2024/8

UR - http://www.scopus.com/inward/record.url?scp=85197523567&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2024.105245

DO - 10.1016/j.ebiom.2024.105245

M3 - 评论/辩论

C2 - 38981160

AN - SCOPUS:85197523567

SN - 2352-3964

VL - 106

SP - 105245

JO - EBioMedicine

JF - EBioMedicine

M1 - 105245

ER -